Physician profile
Reed Hogan
NPI 1023006293
$215,670.65
in general payments reported to CMS, 2019-2025
40 companies · $17K in 2025
The $17K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,162 · 2021: $2,549 · 2022: $35K · 2023: $79K · 2024: $67K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $128K · Travel and Lodging: $28K · Food and Beverage: $5,442 · Consulting Fee: $1,648.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,762.10 |
| Travel and Lodging | $27,848.67 |
| Food and Beverage | $5,442.35 |
| Consulting Fee | $1,648.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $74,072.06 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $47,568.53 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $43,812.11 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $27,777.46 | 2024-2025 | Rezdiffra |
| Ferring International Pharmascience Center US | $4,750.00 | 2019 | |
| Eli Lilly and Company | $3,349.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,994.24 | 2019-2024 | Xifaxan, Trulance |
| Medtronic, INC. | $2,952.87 | 2025 | Interstim, Intellis Adaptivestim |
| Echosens North America, INC. | $2,474.90 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $1,874.80 | 2020-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $1,448.85 | 2019 | |
| Abbvie INC. | $633.98 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $405.07 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $239.04 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $230.46 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $226.70 | 2023 | |
| Ambu INC. | $145.04 | 2020 | |
| Janssen Scientific Affairs, LLC | $92.62 | 2019 | |
| Pentax of America, INC. | $90.51 | 2022 | |
| Alnylam Pharmaceuticals INC. | $68.65 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $43.52 | 2022-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $43.14 | 2023-2024 | Dificid |
| Ardelyx, INC. | $36.07 | 2024-2025 | Ibsrela |
| Fujifilm Healthcare Americas Corporation | $33.91 | 2020 | |
| Novo Nordisk INC | $33.20 | 2025 | Saxenda, Wegovy |
| Ipsen Biopharmaceuticals, INC | $32.21 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $31.34 | 2023 | Sutab, Suflave |
| Pfizer INC. | $29.64 | 2019 | |
| Lilly USA, LLC | $25.16 | 2023 | |
| Qol Medical, LLC | $24.81 | 2023 | Sucraid |
| Janssen Biotech, INC. | $24.69 | 2025 | Tremfya |
| Redhill Biopharma INC. | $23.40 | 2021 | |
| Nestle Healthcare Nutrition INC. | $21.94 | 2022 | |
| Aimmune Therapeutics, INC. | $20.95 | 2025 | Zenpep |
| Capsovision, INC. | $16.30 | 2023 | Capsocam Plus |
| Evoke Pharma, INC. | $12.46 | 2022 | |
| Allergan, INC. | $11.02 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,139.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reed Hogan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.